Brief: Nkgen Biotech Expects To Initiate Phase 1 Clinical Trial For PD In 2H2024
29/04/2024 13:03
April 29 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG (IND) APPLICATION FOR SNK01 NK CELL THERAPY IN PARKINSON’S
DISEASE
* NKGEN BIOTECH INC: EXPECTS TO INITIATE A PHASE 1 CLINICAL
TRIAL
IN PD IN 2H 2024.
Source text for Eikon: ID:nGNX5NR6ny
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program